All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Is CAR T-cell therapy an option for transplant-ineligible patients with DLBCL?
During the PPLC 2022, the Lymphoma Hub spoke with Nilanjan Ghosh, Levine Cancer Institute, Charlotte, US. We asked, Is CAR T-cell therapy an option for transplant-ineligible patients with diffuse large B-cell lymphoma?
Is CAR T-cell therapy an option for transplant-ineligible patients with DLBCL?
Ghosh begins by discussing liso-cel as a therapeutic option for transplant-ineligible patients with diffuse large B-cell lymphoma, outlining a pilot study investigating this. Ghosh describes the study design and results, highlighting the important findings, e.g., response rate and safety.
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox